Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/47/a0/3f/47a03f03-b595-12fe-9dc3-136566910bd5/mza_9141666422414174576.jpg/600x600bb.jpg

Medical Industry Feature

ReachMD

32 episodes

3 days ago

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

Science

Medicine

RSS

All content for Medical Industry Feature is the property of ReachMD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

Science

Medicine

Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data

Medical Industry Feature

7 months ago

Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data

Guest: Jennie Taylor, MD

The FDA approval of vorasidenib marks a new era for mutant isocitrate dehydrogenase (mIDH) gliomas. Approved in 2024 for grade 2 tumors after surgery, it doubled progression-free survival in the INDIGO trial. Dr. Jennie Taylor, Associate Professor of Neurology and Neurological Surgery at the University of California San Francisco, dives into the data and explains what questions remain about long-term use and broader applications.